It has begun: Foxconn amassing army of workers for iPhone 18 Pro assembly
appleinsider - Months ahead of the fall launches, and historically right on time, Apple supply chain partner Foxconn has started to hire a small army of assemblers to build the iPhone 18 Pro.Workers at a Foxconn facility - Image source: FoxconnEach summer, the Apple sup…
AI Summary: Agenus has suspended the BATTMAN clinical trial and announced a follow‑on program called ROBBIN after strategic reassessment, a move that has raised questions about transparency and participant communication. The abrupt pivot highlights tensions between rapid corporate decision‑making and the need to maintain patient trust in oncology research.
The AACR Rare Cancers Initiative: Uniting Researchers, Undoing Barriers, and Unleashing Progress
Steve Schneible / aacr - At the recent AACR Special Conference on Breaking Barriers in the Fight Against Rare Cancers, AACR Immediate Past President Lillian L. Siu, MD, FAACR, announced the AACR Rare Cancers Initiative. Learn more about how this new Initiative will marshal global…
AI Summary: The AACR has unveiled a Rare Cancers Initiative to coordinate researchers, streamline data sharing, and speed therapeutic development for uncommon tumor types. By pooling expertise, funding and networks, the program seeks to overcome the chronic scarcity of trials and resources that leave rare‑cancer patients waiting for attention that’s been hard to come by.
Live attenuated vaccines alone or in combination with an adenovirus-based vaccine protect mice lacking IFN-γ against pneumonic plague
Emily K. Hendrix, Jian Sha, Paul B. Kilgore, Blake H. Neil, Atul K. Verma, Heidi Spratt, Ashok K. Ch / science - Science Translational Medicine, Volume 18, Issue 859, July 2026.
AI Summary: Preclinical work shows that a live attenuated vaccine, alone or combined with an adenovirus vector, protected mice lacking key interferon‑gamma defenses from pneumonic plague. The strategy delivered surprising protection in immunocompromised models, suggesting a potential path forward for vaccines designed to work even when classical immune pathways are impaired.
Breathalyzer can 'sniff out' when your body starts burning fat
medicalxpress - Researchers have developed a breath detector with a chemical sensor that sniffs out when your body is burning fat through a single exhale. Reporting in Device, the handheld, smartphone-assisted device measures acetone—a molecule that is released into the …
AI Summary: Engineers developed a breath-based detector that pinpoints when the body shifts to fat oxidation, and shrank it down to a phone-compatible breathalyser. The device measures volatile markers in exhaled breath to indicate metabolic state, enabling noninvasive, real‑time monitoring of fat burning for weight-loss or metabolic research — because your phone now judges your dinner choices.
Gregory Lesinski: Winship Team Publishes Novel CAR/VIPRa T-Cell Therapy in Science
oncodaily - Gregory Lesinski, Associate Director of Basic Research at Winship Cancer Institute of Emory University, shared on LinkedIn by Sarwish Rafiq, Assistant Professor at the Emory University School of Medicine and […]
AI Summary: Researchers published a novel CAR T‑cell approach exploiting the VIP–VIPR pathway that reprograms cells for superior antitumor activity in preclinical models. The Winship team’s paper reports enhanced tumor killing and durability in laboratory studies, flagging a promising route to improve CAR T efficacy in solid tumors — still very early, but intriguing.
Could this enzyme help remove 'zombie' cells from our tissues?
medicalxpress - Our population is aging. The United Nations reports that by 2050, the number of people age 85 and older on our planet is set to triple. But a longer life span isn't the same as a longer health span (the number of years we spend healthy). Salk Institute sc…
AI Summary: Researchers identified an enzyme that selectively targets senescent “zombie” cells, restoring tissue function in preclinical models and hinting at anti‑aging and therapeutic possibilities. The findings generated excitement for potential disease‑modifying strategies, but experts caution that translating enzyme‑based fixes from mice to humans will require careful safety studies and sober expectations.
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial
Adam D. Cohen / nature - Nature Medicine, Published online: 22 July 2026; doi:10.1038/s41591-026-04522-3In a phase 1 trial, the maximum tolerated dose for an FcRH5-containing bispecific T cell engager was not reached, and there was an encouraging response rate in patients with re…
AI Summary: A phase 1 study of the FcRH5×CD3 bispecific antibody cevostamab reported manageable safety and early signals of activity in relapsed or refractory multiple myeloma. Investigators outlined dosing, adverse events and preliminary responses, setting the stage for larger studies and combination trials as patients and advocates watch for broader access to T‑cell‑engaging therapies.
$10B M&A Deal Pays Off With GSK’s First Lung Cancer Drug Approval
Frank Vinluan / medcitynews - GSK drug Jideytro received FDA approval for treating advanced cases of non-small cell lung cancer driven by ROS1 alterations. This molecule came from Nuvalent, which GSK recently acquired for $10.6 billion. The post $10B M&A Deal Pays Off With GSK’s First…
AI Summary: GSK has won FDA approval for its first lung cancer drug, a gene-targeting therapy that validates the company’s heavy investment and recent M&A strategy. The approval follows pivotal trial evidence of clinical benefit and positions GSK competitively in thoracic oncology, offering a new therapeutic choice for patients with the relevant molecular profile.
6-year-old in China dies after experimental treatment, investigation finds, raising questions about the country's gene therapy regulations
livescience - A young girl in China died after being given an experimental gene therapy intended to treat a neurodevelopmental syndrome, an investigation by Science and Retraction Watch revealed.
AI Summary: An investigation found a six‑year‑old patient died following an experimental gene‑editing treatment in China, and that the fatality was not promptly disclosed. The case has reignited scrutiny of the country’s gene therapy oversight and raised urgent questions about trial transparency, consent and regulatory enforcement.